Thymidine phosphorylase expression and effect of doxifluridine: a phase II study.
Doxifluridine (5'-DFUR), an active intermediate metabolite of capecitabine, is converted to 5-fluorouracil by thymidine phosphorylase (TP). We used immunohistochemical staining to investigate the relation between TP expression and 5'-DFUR effects in 40 patients with advanced/recurrent lung metastases from colorectal cancer. Cox regression analysis suggested that TP-positive cancer cells (risk ratio 3.72), were independent factors in survival whereas factors in progression-free survival were TP-positive cancer cells (2.93), and TP-positive stromal cells (0.24). It is suggested that TP expression in cancer cells and in stromal cells are opposite prognostic factors in patients treated with 5'-DFUR.
Sadahiro
S
S
Department of Surgery, School of Medicine, Tokai University, Bohseidai, Isehara, Kanagawa 259-1193, Japan. sadahiro@is.icc.u-tokai.ac.jp
Otani
Y
Y
Oya
K
K
Ike
H
H
Shimada
H
H
Yamaguchi
S
S
Hiki
Y
Y
Fujita
H
H
Mitomi
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013939:Thymidine Phosphorylase / Q000378:metabolism*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; D013939:Thymidine Phosphorylase; C025034:doxifluridine